HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

HERZLIYA, Israel and CALGARY, AB, March 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its ...

Bermuda Electric Light Company Limited (BELCO) is Bermuda's sole supplier of electricity, operating a generating plant and transmission and distribution systems throughout the Island. BELCO’s Mission ...

The U.S. and its major trading partners have agreed to reciprocal tariff elimination for pharmaceutical products and chemicals used in drug production for the past 30 years, according to the U.S ...

Investing.com - Crinetics Pharma (NASDAQ: CRNX) reported second quarter EPS of $-0.94, $0.07 worse than the analyst estimate of $-0.87. Revenue for the quarter came in at $1M... ByInvesting.com ...

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $300.00. The company’s shares closed yesterday at $245.20.

Gland Pharma Ltd on Tuesday (February 25) announced that America's drug regulatory watchdog has completed a crucial inspection of its Andhra Pradesh facility. In a regulatory filing, Gland Pharma said ...

Its time for Indian pharma companies to look beyond the U.S. market as the Trump administration has threatened to impose 25% tariff on pharmaceutical imports. This move would disrupt India’s ...

Mankind Pharma, India’s fourth largest drugmaker by domestic sales, is setting its sights on anti-obesity drugs like Semaglutide, better known by brand names Ozempic and Wegovy, which goes off ...

Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on Verona Pharma (VRNA – Research Report) today and set a price target of $68.00. The company’s shares closed last Friday at $67.96.

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. The boss of German healthcare company Stada says his business is a better bet than Big Pharma ...